This meta-analysis showed that 18F-PSMA-1007 PET/CT has a higher diagnostic efficacy for prostate cancer both in the setting of primary prostate cancer and biochemical recurrence, as compared to other PSMA ligands. This evidence concerns the gene FOLH1 and prostate cancer.